RNS Number:4789N
AIM
11 July 2003


ANNOUNCEMENT TO BE MADE BY PROSPECTIVE AIM COMPANY AT LEAST 10 BUSINESS DAYS PRIOR TO ADMISSION

COMPANY NAME:
CeNeS Pharmaceuticals plc ("CeNeS" or "the Company")
COMPANY ADDRESS:
COMPASS HOUSE, VISION PARK, CHIVERS WAY, HISTON, CAMBRIDGE
COMPANY POSTCODE:
CB2 9ZR
COUNTRY OF INCORPORATION:
Scotland
COMPANY BUSINESS:
Drug development for the treatment of pain
DETAILS OF SECURITIES TO BE ADMITTED (ie, where known, number of shares, nominal value and issue price):
174, 412, 968 Ordinary shares of 10p each
CAPITAL TO BE RAISED ON ADMISSION
Nil
FULL NAMES AND FUNCTIONS OF DIRECTORS, INCLUDING SHADOW AND PROPOSED DIRECTORS:
Alan Gilbert Goodman - Executive Chairman

Neil Robert Clark - Chief Operating Officer and Finance Director

Thomas Ronald Irwin - Non-Executive Director

Timothy Ray Wright - Non-Executive Director
PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL
STATING WHETHER BEFORE OR AFTER ADMISSION:
Elan Corporation plc            9.7%

NY Nominees Ltd                 7.7%

A G Goodman (Exec Chairman)     7.8%

D Roach                         6.8%

Pershing Keen Nominees Ltd      4.5%

Prelude Trust plc               3.4%

NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (G).
None
ACCOUNTING REFERENCE DATE:
31 December
EXPECTED ADMISSION DATE:
8TH AUGUST 2003
NAME AND ADDRESS OF NOMINATED ADVISER:
Evolution Beeson Gregory
NAME AND ADDRESS OF NOMINATED BROKER:
Evolution Beeson Gregory
DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM WITH A STATEMENT THAT
THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES.
No AIM Admission document - Company moving from Official List
DATE OF NOTIFICATION:
11 JULY 2003
NEW/ UPDATE:
New
THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED:
UKLA Official List
THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED:
MARCH 1997
CONFIRMATION THAT THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORY REQUIREMENTS INVOLVED IN HAVING ITS
SECURITIES TRADED UPON SUCH A MARKET:
The Company confirms that it has complied with the legal and regulatory requirements associated with listing on
the Official List
AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THE
LAST TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE:
WWW.CENES.COM
DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILS
OF ITS INVESTMENT STRATEGY
THE DEVELOPMENT OF DRUG COMPOUNDS FOR THE TREATMENT OF PAIN
A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURRED
SINCE THE END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED:
None
A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT ITS WORKING CAPITAL WILL BE
INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION:
The directors of CeNeS have no reason to believe that its working capital will be insufficient for at least
twelve months from the date of its admission
DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES:
None
A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING TRANSACTIONS IN ITS SECURITIES:
The Company's securities are settled within Crest
A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO ITS SECURITIES:
WWW.CENES.COM from 14 July 2003
INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC:
None
A WEBSITE ADDRESS OF A PAGE CONTAINING ITS LATEST PUBLISHED ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE A
FINANCIAL YEAR END NOT MORE THAN NINE MONTHS PRIOR TO ADMISSION. THE ACCOUNTS MUST BE PREPARED ACCORDING TO UK OR
US GAAP OR INTERNATIONAL ACCOUNTING STANDARDS:
WWW.CENES.COM from 14 July 2003






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PAAGUUCUMUPWGQG